FindTrial
Sign In

Paroxetine CR

DRUG10 trials

Sponsors

GlaxoSmithKline, Medical University of South Carolina, Inje University, Duke University, Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions

DepressionDepressive DisorderDepressive Disorder, MajorFibromyalgia SyndromeIrritable Bowel SyndromeMajor Depressive DisorderMajor Depressive Disorder (MDD)Mental Disorders

Phase 3

Depression Study In Elderly Patients
CompletedNCT00067444
GlaxoSmithKlineDepressive Disorder, Major, Major Depressive Disorder (MDD)
Start: 2003-06-30End: 2005-01-31Updated: 2016-09-01
A Local Register Study For Major Depression Of Paroxetine Controlled Release
CompletedNCT00368303
GlaxoSmithKlineDepressive Disorder, Major, Major Depressive Disorder (MDD)
Start: 2006-12-31Target: 362Updated: 2012-06-04
Safety and Tolerability of Oral OPC-34712 as Adjunctive Therapy in Adults With Major Depressive Disorder (the Orion Trial)
CompletedNCT01360866
Otsuka Pharmaceutical Development & Commercialization, Inc.Depression, Depressive Disorder, Depressive Disorder, Major +2
Start: 2011-10-31End: 2017-05-18Updated: 2018-09-17
Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms
NCT05637671
Cairo UniversityVasomotor Symptoms
Start: 2022-02-10End: 2023-12-31Target: 146Updated: 2023-02-08

Phase 4

Major Depressive Disorder Study In Adults
CompletedNCT00049972
GlaxoSmithKlineMajor Depressive Disorder
Start: 2002-09-30End: 2003-09-30Target: 646Updated: 2017-09-11
Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence
CompletedNCT00330239
Medical University of South CarolinaPTSD
Start: 2003-01-31End: 2005-05-31Target: 25Updated: 2007-10-03
Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release
NCT00492414
Inje UniversityPanic Disorder
Updated: 2007-08-08
Paroxetine-CR (Paxil-CR) in the Treatment of Patients With Fibromyalgia Syndrome
CompletedNCT00610610
Duke UniversityFibromyalgia Syndrome
Start: 2002-01-31End: 2002-12-31Updated: 2013-06-20
Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)
CompletedNCT00610909
Duke UniversityIrritable Bowel Syndrome
Start: 2002-01-31End: 2002-12-31Updated: 2013-06-20
Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients
WithdrawnNCT01916200
GlaxoSmithKlineDepressive Disorder
Start: 2014-01-31End: 2014-09-30Updated: 2014-07-16

Related Papers

A Multicenter, Open-Label Study to Evaluate the Long-term Safety and Efficacy of Adjunctive Brexpiprazole 2 mg Daily in Japanese Patients with Major Depressive Disorder
CNS Drugs2024-10-182 citations
Changes in Metabolic Parameters and Body Weight in Patients With Prediabetes Treated With Adjunctive Brexpiprazole for Major Depressive Disorder
The Journal of Clinical Psychiatry2023-08-244 citations
Changes in Metabolic Parameters and Body Weight in Patients With Major Depressive Disorder Treated With Adjunctive Brexpiprazole
The Journal of Clinical Psychiatry2019-10-0112 citations
A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
Journal of Clinical Psychopharmacology2019-04-0224 citations
History of depressive and anxiety disorders and paroxetine response in patients with irritable bowel syndrome: post hoc analysis from a placebo-controlled study.
2008-01-016 citations